Literature DB >> 15023557

The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.

Koichiro Kumagai1, Hideko Nakashima, Keijiro Saku.   

Abstract

OBJECTIVE: It has been recently reported that AF is associated with tissue inflammation. Statins reduce C-reactive protein (CRP) levels. However, the effect of statin on atrial fibrillation (AF) is unclear. The purpose of the present study was to evaluate the effect of statin on AF in a canine sterile pericarditis model.
METHODS: Sterile pericarditis was created in 20 dogs randomly assigned to two groups: a control group (10 dogs) and an atorvastatin treatment group (10 dogs). Atorvastatin was administered orally (2 mg/kg/day) beginning 1 week before the operation until the end of the study. Before and 2 days after the operation, CRP levels, the duration of induced AF, the atrial effective refractory period (AERP), and intra-atrial conduction time were determined.
RESULTS: Before the operation, there were no significant differences in any of the parameters between the two groups. On the second postoperative day, the atorvastatin group had a lower CRP level (7.6+/-0.5 versus 11.7+/-1.3 mg/dl, P<0.0001), a shorter AF duration (177+/-57 versus 534+/-189 s, P<0.0001), a longer AERP (138+/-6 versus 130+/-6 ms, P<0.01), and a shorter intra-atrial conduction time (46+/-3 versus 51+/-5 ms, P<0.01) than the control group.
CONCLUSIONS: Atorvastatin can prevent maintenance of AF by inhibiting inflammation in the canine sterile pericarditis model. Atorvastatin may thus be a novel therapeutic agent for AF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023557     DOI: 10.1016/j.cardiores.2004.01.018

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  52 in total

Review 1.  Statin therapy in cardiovascular diseases other than atherosclerosis.

Authors:  Dominique Beaudry; Kenneth E Stone; Suzanne Wetherold; John Hemphill; Dat Do; John McClish; Robert Chilton
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

2.  Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.

Authors:  Ibrahim R Hanna; Brent Heeke; Heather Bush; Lynne Brosius; Diane King-Hageman; Samuel C Dudley; John F Beshai; Jonathan J Langberg
Journal:  Heart Rhythm       Date:  2006-05-09       Impact factor: 6.343

3.  Pravastatin treatment before coronary artery bypass grafting for reduction of postoperative atrial fibrillation.

Authors:  Kiyoshi Tamura; Hirokuni Arai; Fusahiko Ito; Takeshi Someya; Tomohiro Ushiyama; Naoto Miyagi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-03-11

Review 4.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 5.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

6.  Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation.

Authors:  Jordi Heijman; Azinwi Phina Muna; Tina Veleva; Cristina E Molina; Henry Sutanto; Marcel Tekook; Qiongling Wang; Issam H Abu-Taha; Marcel Gorka; Stephan Künzel; Ali El-Armouche; Hermann Reichenspurner; Markus Kamler; Viacheslav Nikolaev; Ursula Ravens; Na Li; Stanley Nattel; Xander H T Wehrens; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-07-30       Impact factor: 17.367

7.  Inflammation in lone atrial fibrillation.

Authors:  Shu-Yuan Yao; Jian-Min Chu; Ke-Ping Chen; Min Tang; Pi-Hua Fang; Fang-Zheng Wang; Shu Zhang
Journal:  Clin Cardiol       Date:  2009-02       Impact factor: 2.882

Review 8.  Pleiotropic effects of statins in atrial fibrillation patients: the evidence.

Authors:  Hadi Ar Hadi; Wael Al Mahmeed; Jassim Al Suwaidi; Samer Ellahham
Journal:  Vasc Health Risk Manag       Date:  2009-06-29

Review 9.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.

Authors:  Irene Savelieva; Antonios Kourliouros; John Camm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-25       Impact factor: 3.000

10.  Effects of rosuvastatin on atrial nerve sprouting and electrical remodeling in rabbits with myocardial infarction.

Authors:  Xujuan Hou; Yujiao Zhang; Ximin Wang; Shaohua Zheng; Yinglong Hou; Mei Gao
Journal:  Int J Clin Exp Med       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.